Apretude | search
Click here to view Apretude news from 60+ newspapers.
Bookmark or Share- APRETUDE (cabotegravir) Label - Food and Drug AdministrationAPRETUDE is an HIV-1 integrase strand transfer inhibitor (INSTI) indicated in at-risk adults and adolescents weighing at least 35 kg for PrEP to reduce the risk of sexually acquired HIV-1 infection. Individuals must have a negative HIV-1 test prior to initiating APRETUDE (with or without an oral lead-in with oral cabotegravir) for HIV-1 PrEP.
- ViiV Healthcare announces FDA approval of Apretude (cabotegravir ...Apretude is an integrase strand transfer inhibitor (INSTI). INSTIs, like cabotegravir extended-release injectable suspension, inhibit HIV replication by preventing the viral DNA from integrating into the genetic material of human immune cells (T-cells). This step is essential in the HIV replication cycle and is also responsible for establishing ...
- Long-acting PrEP | APRETUDE (cabotegravir)Before receiving your first APRETUDE injection, your healthcare provider may have you take 1 oral cabotegravir tablet 1 time a day for 1 month (at least 28 days) to assess how well you tolerate cabotegravir. APRETUDE is a long-acting medicine and may stay in your body for 12 months or longer after your last injection.
- FDA Approves First Injectable Treatment for HIV Pre-Exposure PreventionDecember 20, 2021. Today, the U.S. Food and Drug Administration approved Apretude (cabotegravir extended-release injectable suspension) for use in at-risk adults and adolescents weighing at least ...
- Cabotegravir - Patient | NIH - ClinicalinfoViiV Healthcare. Main number: 877-844-8872. Patient assistance (ViiV Connect): 844-588-3288. Last Reviewed: February 7, 2024. Cabotegravir can cause serious side effects, including skin rash, allergic reactions, liver problems, and mood changes. See guidelines for use in people with HIV.
More
